X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Major Depressive Disorder

    AbbVie to Acquire Gilgamesh Pharmaceuticals’ Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline

    FDA Approved Papzimeos

    The U.S. FDA Approved Papzimeos for RRP Treatment in Adults

    Biosimilar Ranibizumab

    Lupin, Sandoz Collab to Commercialise Biosimilar Ranibizumab

    FDA Approves Brinsupri by Insmed for Chronic Lung Condition

    FDA Approves Brinsupri by Insmed for Chronic Lung Condition

    FDA Approves Brain Tumour Treatment Modeyso by Jazz Pharma

    FDA Approves Brain Tumour Treatment Modeyso by Jazz Pharma

    Thermo Fisher New HMW Kit Powers Long Read DNA Sequencing

    Thermo Fisher New HMW Kit Powers Long-Read DNA Sequencing

    Taiwan Grants Full Approval for NEFECON IgAN Treatment

    Taiwan Grants Full Approval for NEFECON IgAN Treatment

    Agentic AI in Pharma Transforming RD to Commercialisation

    Agentic AI in Pharma: Transforming R&D to Commercialisation

    New Software to Predict Cell Activity for Cancer Research

    New Software to Predict Cell Activity for Cancer Research

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Major Depressive Disorder

    AbbVie to Acquire Gilgamesh Pharmaceuticals’ Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline

    FDA Approved Papzimeos

    The U.S. FDA Approved Papzimeos for RRP Treatment in Adults

    Biosimilar Ranibizumab

    Lupin, Sandoz Collab to Commercialise Biosimilar Ranibizumab

    FDA Approves Brinsupri by Insmed for Chronic Lung Condition

    FDA Approves Brinsupri by Insmed for Chronic Lung Condition

    FDA Approves Brain Tumour Treatment Modeyso by Jazz Pharma

    FDA Approves Brain Tumour Treatment Modeyso by Jazz Pharma

    Thermo Fisher New HMW Kit Powers Long Read DNA Sequencing

    Thermo Fisher New HMW Kit Powers Long-Read DNA Sequencing

    Taiwan Grants Full Approval for NEFECON IgAN Treatment

    Taiwan Grants Full Approval for NEFECON IgAN Treatment

    Agentic AI in Pharma Transforming RD to Commercialisation

    Agentic AI in Pharma: Transforming R&D to Commercialisation

    New Software to Predict Cell Activity for Cancer Research

    New Software to Predict Cell Activity for Cancer Research

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

J&J Investment of $2B Boosts US Drug Manufacturing Capacity

API PA by API PA
26th August 2025
in Americas, Facilities & Operation, Manufacturing, News
JJ Investment

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Johnson & Johnson, an industry leader known for its global healthcare innovation, unveiled plans to increase its presence in the state of North Carolina through the creation of a 160,000+ square foot manufacturing facility at FUJIFILM’s newly constructed biopharmaceutical manufacturing site at Holly Springs. This $2 billion, decade-long investment will expand production capacity nationwide and is expected to create approximately 120 new positions in the state.

Over the coming months, Johnson & Johnson (J&J) also plans to outline additional advanced manufacturing projects across the United States, alongside enhancements to its existing domestic facilities. J&J investment in North Carolina, along with other initiatives, underscores the Company’s strategy to strengthen U.S. production of advanced medicines and to ensure that the majority of treatments can be developed to meet patient needs.

“Johnson & Johnson has more manufacturing facilities in the U.S. than in any other country, and we continue to strengthen our presence here,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “With the recent signing of the One Big Beautiful Bill Act, we continue to expand our investment in the U.S. to lead the next era of healthcare innovation.”

Earlier this year, J&J investment plan of $55 billion to enhance U.S. manufacturing, research and development, and technology capacity over the next four years was announced. 

Construction is also moving forward steadily at the Wilson, North Carolina facility, which will have over 500 employees at full capacity and will create about 5,000 jobs during construction. Apart from infrastructure, Johnson & Johnson also remains committed to research and development spending, especially in key categories including oncology, neuroscience, immunology, cardiovascular disease, and robotic surgery.

FUJIFILM’s Holly Springs biopharmaceutical plant will allow Johnson & Johnson to further enhance its manufacturing capacity in the U.S. Across the country, these strategic investments are expected to generate thousands of jobs.

Tags: Big Pharma
Previous Post

Pharmaceutical Tariff Agreed at 15% Under US-EU Trade Deal

Next Post

AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline

Related Posts

Major Depressive Disorder
Americas

AbbVie to Acquire Gilgamesh Pharmaceuticals’ Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline

27th August 2025
Pharmaceutical Tariff
Americas

Pharmaceutical Tariff Agreed at 15% Under US-EU Trade Deal

26th August 2025
FDA Approved Papzimeos
Americas

The U.S. FDA Approved Papzimeos for RRP Treatment in Adults

25th August 2025
US Pharma Supply Chain
Americas

Trump Signs Executive Order to Boost US Pharma Supply Chain

20th August 2025
Biosimilar Ranibizumab
Asia

Lupin, Sandoz Collab to Commercialise Biosimilar Ranibizumab

18th August 2025
FDA Approves Brinsupri by Insmed for Chronic Lung Condition
Americas

FDA Approves Brinsupri by Insmed for Chronic Lung Condition

14th August 2025
Next Post
Major Depressive Disorder

AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In